Evidence map›Paper›PMID 41613042›Full record

ArticleNeuro-oncology advances

Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma.

John Y Rhee, Juan Pablo Ospina Botero, Thomas Nelson, Kun Wei Song, Michael W Parsons, Elizabeth R Gerstner, Jorg Dietrich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John Y RheeCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.ORCID https://orcid.org/0000-0002-2081-5667
Juan Pablo Ospina BoteroCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.
Thomas NelsonDivision of Neuro-Oncology, Department of Neurosurgery, University of California San Francisco, San Francisco.
Kun Wei SongDepartment of Neurology, Stanford University Medical Center, Palo Alto.
Michael W ParsonsDepartment of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.
Elizabeth R GerstnerDepartment of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.
Jorg DietrichDepartment of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.ORCID https://orcid.org/0000-0001-8291-0136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

"Pseudoprogression" following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (

Indexed as

glioblastomaimmune checkpoint inhibitorpseudoprogression

Identifiers

PMID41613042
PMCPMC12850524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.